Aoxing Pharmaceutical Company Inc.
AXN
AXN was delisted on the 16th of October, 2017.
10 hedge funds and large institutions have $128K invested in Aoxing Pharmaceutical Company Inc. in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
52% more capital invested
Capital invested by funds: $84K → $128K (+$44K)
9% less funds holding
Funds holding: 11 → 10 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$28.7K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$10.9K |
| 4 |
Bank of New York Mellon
New York
|
+$5.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$3.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $42K | +$20K | +46,435 | +82% |
|
|
2
Renaissance Technologies
New York
| $35K | +$28.7K | +66,700 | +323% |
|
|
PAM
3
Panagora Asset Management
Boston,
Massachusetts
| $20K | +$10.9K | +25,431 | +108% |
|
4
Barclays
London,
United Kingdom
| $10K | – | – | – |
|
|
VKH
5
Virtu KCG Holdings
New York
| $6K | -$3.15K | -7,323 | -31% |
|
|
EWM
6
Evercore Wealth Management
New York
| $5K | – | – | – |
|
|
7
Bank of New York Mellon
New York
| $5K | +$5.01K | +11,664 | New |
|
|
FWM
8
Focused Wealth Management
Newburgh,
New York
| $3K | – | – | – |
|
9
Creative Planning
Overland Park,
Kansas
| $2K | – | – | – |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$20K | -63,789 | Closed |
|
|
11
UBS Group
Zurich,
Switzerland
| – | -$8K | -25,556 | Closed |
|
AXN Hedge Fund Activity: Q1 2017 in Review
10 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical Company Inc. (AXN) for Q1 2017, worth a combined $128K — up 52% from $84K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of AXN and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $28.7K. The largest seller was Citadel Advisors, exiting entirely with an estimated $20K sold.
- 10 institutional investors held Aoxing Pharmaceutical Company Inc. (AXN) as of Q1 2017, down from 11 in Q4 2016.
- Funds reported $128K of Aoxing Pharmaceutical Company Inc. stock for Q1 2017, up 52% quarter-over-quarter.
- 1 fund opened new Aoxing Pharmaceutical Company Inc. positions in Q1 2017 and 2 closed out, a net change of -1 holder.
- The largest Aoxing Pharmaceutical Company Inc. buyer in Q1 2017 was Renaissance Technologies, an estimated $28.7K added.
- The largest Aoxing Pharmaceutical Company Inc. seller in Q1 2017 was Citadel Advisors, an estimated $20K sold.
Based on aggregated 13F filings for Q1 2017.